Clinical trials: Oesophageal Cancer Nos
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Cancer, Lung, Cancer of Esophagus
Radiogenomics in Aerodigestive Tract Cancers
Aerodigestive tract cancers are common malignancies. These cancers were ranked to be top-ten cancer-related deaths in Taiwan. Although many new target therapies and immunotherapies have emerged, many of the treatment eventually…
- Conditions
- Cancer, Lung, Cancer of Esophagus, Cancer of Head and Neck
- Trial name
- NCT04314349
- Where
- Taiwan
- Volunteers
- 139 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer .
- Conditions
- Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
- Trial name
- RICE (NCT05621707)
- Testing
- chemotherapy combined with PD-1 inhibitors
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Cancer, Pain
Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy
This pilot clinical trial studies a pain management smartphone application for monitoring pain in patients with locally advanced head and neck cancer who are undergoing radiation therapy.
- Conditions
- Head and Neck Cancer, Pain, Lung Cancer, Esophageal Cancer
- Trial name
- NCT02324881
- Testing
- Telephone-Based Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Cancer
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI.
- Trial name
- PIONEER (NCT04846309)
- Testing
- Radiation, FMISO PET CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Esophageal Cancer, Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.
- Trial name
- NCT06499298
- Testing
- Nivolumab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Carcinoma in Situ AJCC V7
A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
The purpose of this study was to compare the efficacy and safety of Photodynamic therapy (PDT) and Endoscopic submucosal (ESD) dissection in the treatment of early esophageal cancer.
- Trial name
- NCT05208775
- Testing
- PDT, ESD
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Cancer Stage III
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer
This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III…
- Trial name
- FOLFOX (NCT00578201)
- Testing
- radiochemotherapy,combination Cetuximab-FOLFOX
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric Cancer, Gastric Adenocarcinoma
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
- Trial name
- ANGEL (NCT03042611)
- Testing
- Rivoceranib
- Where
- 95 sites in United States, France and 10 more
- Volunteers
- 460 people
- Sponsor
- Elevar Therapeutics
Lung Cancer, Esophageal Cancer
Assessment of Patient Frailty Prior to Thoracic Surgery
Determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung…
- Trial name
- NCT02803281
- Testing
- Frailty Assessment
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer, Precancerous Condition
Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus
RATIONALE: A tethered capsule endoscope may be as effective as standard sedated endoscopy of the esophagus, stomach, and duodenum in screening for Barrett esophagus.
- Trial name
- NCT00903136
- Testing
- questionnaire administration, comparison of screening methods, diagnostic endoscopic procedure
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Esophageal Cancer
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer.
- Trial name
- NCT02138929
- Testing
- Everolimus, LDE 225
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Esophagitis
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer
This study will evaluate whether a Whole Food Intervention reduces the frequency or severity of esophagitis in patients receiving treatment for non-small cell lung cancer.
- Trial name
- NCT02575391
- Testing
- Whole Food Intervention
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Providence Health & Services
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Folfox+Irinotecan+Chemort In Esophageal Cancer
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer…
- Trial name
- NCT04656041
- Testing
- FOLFOX/ nal-IRI, Paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophageal Cancer
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
1. Research methods Constructed the "Manual for Graded Management of Postoperative Symptoms of Esophageal Cancer" and developed continuous care Procedures. 2.
- Trial name
- NCT07187154
- Testing
- Smart Symptom Management Program
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.